Can we rationally design promiscuous drugs?
暂无分享,去创建一个
[1] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[2] Ronald W. Davis,et al. Role of duplicate genes in genetic robustness against null mutations , 2003, Nature.
[3] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[4] J. Halpert,et al. Structures of cytochrome P450 3A4. , 2005, Trends in biochemical sciences.
[5] Christopher W Murray,et al. Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.
[6] Charles Kung,et al. Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] Jan Balzarini,et al. Phenylethylthiazolylthiourea (PETT) Non-nucleoside Inhibitors of HIV-1 and HIV-2 Reverse Transcriptases , 2000, The Journal of Biological Chemistry.
[8] Dan S. Tawfik,et al. The 'evolvability' of promiscuous protein functions , 2005, Nature Genetics.
[9] A. Brown. HERG block, QT liability and sudden cardiac death. , 2005, Novartis Foundation symposium.
[10] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[11] Andrew Howard,et al. Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam , 1993 .
[12] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[13] J. Lehár,et al. Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[14] Gary D Bader,et al. Global Mapping of the Yeast Genetic Interaction Network , 2004, Science.
[15] T. Hampton,et al. "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance. , 2004, JAMA.
[16] B. Stockwell,et al. Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.
[17] B. Berkhout. HIV-1 Evolution under Pressure of Protease Inhibitors: Climbing the Stairs of Viral Fitness , 1999, Journal of Biomedical Science.
[18] F. Sams-Dodd. Target-based drug discovery: is something wrong? , 2005, Drug discovery today.
[19] Joel L. Sussman,et al. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica , 1998, Journal of Physiology-Paris.
[20] Simon K. Mencher,et al. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) , 2005, BMC clinical pharmacology.
[21] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[22] J. Casida,et al. Detoxification of α- and β-Thujones (the Active Ingredients of Absinthe): Site Specificity and Species Differences in Cytochrome P450 Oxidation in Vitro and in Vivo , 2001 .
[23] S. Lindquist,et al. Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi , 2005, Science.
[24] D. Stuart,et al. Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[26] Mark C. Fishman,et al. Pharmaceuticals: A new grammar for drug discovery , 2005, Nature.
[27] M. Newman. Properties of highly clustered networks. , 2003, Physical review. E, Statistical, nonlinear, and soft matter physics.
[28] B. Shoichet,et al. High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.
[29] Richard Morphy,et al. From magic bullets to designed multiple ligands. , 2004, Drug discovery today.
[30] D I Stuart,et al. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.
[31] A. Sands,et al. Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.
[32] L. Moore,et al. The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity , 2001, Science.
[33] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[34] A. Fliri,et al. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. , 2005, Journal of medicinal chemistry.
[35] A. Fliri,et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.
[36] Alex M Aronov,et al. Toward a pharmacophore for kinase frequent hitters. , 2004, Journal of medicinal chemistry.
[37] B. Garvik,et al. Principles for the buffering of genetic variation. , 2001 .
[38] B. Stockwell. Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.
[39] Erik De Clercq,et al. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection , 1998 .
[40] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[41] Stephen K Burley,et al. A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[42] Gennady M Verkhivker,et al. Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes. , 1996, Proteins.
[43] Jose Cosme,et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.
[44] A. Barabasi,et al. Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.
[45] B. Shoichet,et al. Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.
[46] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[47] Gabriele Cruciani,et al. Predictive models for hERG potassium channel blockers. , 2005, Bioorganic & medicinal chemistry letters.
[48] L. Moore,et al. Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. , 2005, Molecular endocrinology.
[49] D I Stuart,et al. Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding* , 2000, The Journal of Biological Chemistry.
[50] Beyond CAR and PXR. , 2005, Current drug metabolism.
[51] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[52] D I Stuart,et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. , 2001, Journal of molecular biology.
[53] M. Redinbo. Promiscuity: what protects us, perplexes us. , 2004, Drug discovery today.
[54] D. Stammers,et al. The Phenylmethylthiazolylthiourea Nonnucleoside Reverse Transcriptase (RT) Inhibitor MSK-076 Selects for a Resistance Mutation in the Active Site of Human Immunodeficiency Virus Type 2 RT , 2004, Journal of Virology.
[55] A. Cavalli,et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.
[56] Andrzej Kloczkowski,et al. Protein Promiscuity: Drug Resistance and Native Functions—HIV-1 Case , 2005, Journal of biomolecular structure & dynamics.
[57] David I Stuart,et al. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. , 2004, Journal of medicinal chemistry.
[58] A. Fliri,et al. Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[59] Jose Cosme,et al. Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.
[60] L. Moore,et al. The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution , 2000 .
[61] F. Gonzalez. Cytochrome P450 humanised mice , 2004, Human Genomics.
[62] Albert,et al. Emergence of scaling in random networks , 1999, Science.
[63] Celia A Schiffer,et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. , 2005, Journal of medicinal chemistry.
[64] Jean-Pierre Marquette,et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. , 2002, Journal of medicinal chemistry.
[65] Gennady M Verkhivker,et al. Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[66] Kazuo Koyama,et al. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. , 2003, Bioorganic & medicinal chemistry.
[67] S. Frantz. Drug discovery: Playing dirty , 2005, Nature.
[68] A. Wagner. Robustness against mutations in genetic networks of yeast , 2000, Nature Genetics.
[69] Celia A Schiffer,et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. , 2005, Journal of medicinal chemistry.
[70] W. Sneader. Drug prototypes and their exploitation , 1996 .
[71] Turning from monogamy to strategic promiscuity. , 2004, Drug discovery today.